Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income (2016 - 2025)

Ani Pharmaceuticals' Net Income history spans 15 years, with the latest figure at $27.5 million for Q4 2025.

  • For Q4 2025, Net Income rose 367.96% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $78.3 million, up 522.94%, while the annual FY2025 figure was $78.3 million, 522.94% up from the prior year.
  • Net Income for Q4 2025 was $27.5 million at Ani Pharmaceuticals, up from $26.6 million in the prior quarter.
  • Across five years, Net Income topped out at $27.5 million in Q4 2025 and bottomed at -$24.2 million in Q3 2024.
  • The 5-year median for Net Income is -$1.1 million (2021), against an average of -$590050.0.
  • The largest annual shift saw Net Income crashed 23365.12% in 2022 before it skyrocketed 1144.71% in 2024.
  • A 5-year view of Net Income shows it stood at -$24.1 million in 2021, then surged by 82.53% to -$4.2 million in 2022, then soared by 127.37% to $1.2 million in 2023, then plummeted by 990.12% to -$10.3 million in 2024, then skyrocketed by 367.96% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Net Income are $27.5 million (Q4 2025), $26.6 million (Q3 2025), and $8.5 million (Q2 2025).